This document discusses the role of adjuvant radiation therapy in head and neck cancers. It begins by outlining the use of radical and palliative treatment for stage III and IV diseases. It then reviews several landmark studies that established the benefits of postoperative radiation therapy (PORT) over surgery alone in improving local control and survival. Key factors that determine the need for adjuvant therapy like extracapsular extension, positive margins, and T3/T4 stage are discussed. The document also addresses optimal radiation dose, timing, use of concurrent chemotherapy and altered fractionation schedules based on evidence from clinical trials. While targeted therapies in the adjuvant setting have not proven beneficial so far, ongoing studies are exploring their potential role.
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Santam Chakraborty
A journal club presentation comparing and contrasting the EORTC and RTOG trials of concurrent chemoradiation in Head Neck Cancers in the post operative setting.
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
Small Presentation where the benefit of addition of induction / neoadjuvant chemotherapy to concurrent chemoradiation in head neck cancers is explored.
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Santam Chakraborty
A journal club presentation comparing and contrasting the EORTC and RTOG trials of concurrent chemoradiation in Head Neck Cancers in the post operative setting.
Induction chemotherapy followed by concurrent ct rt versus ct-rt in advanced ...Santam Chakraborty
Small Presentation where the benefit of addition of induction / neoadjuvant chemotherapy to concurrent chemoradiation in head neck cancers is explored.
T4 Larynx cancer can be treated with ChemoradiotherapyAjeet Gandhi
Traditionally, T4 larynx cancers are recommended to undergo surgery as the primary modality of treatment. However, a select group of patients may be treated with CTRT
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Role of Post-op Radiotherapy in Head and Neck Cancers
1. Role of Adjuvant Radiation Therapy
in Head and Neck Cancers
Dr. Ashutosh Mukherji
Sr. Consultant Radiation Oncologist
and Academic Coordinator
Yashoda Cancer Institute, Hyderabad
CME: Head and Neck Oncology: Controversies and Consensus,
28th November 2018, Nizam’s Institute of Medical Sciences
2. Stage III and IV
Radical Treatment
Palliative Treatment
3. Advanced disease-Radical Rx - III&IVa
1.Ca oral cavity(Stage III,IVA)
2.Ca larynx -T4a (Cartilage)
3.T4a hypopharynx (Cartilage)
4.T3 Hypopharynx-Non responders
Surgery
Post op
XRT+/-chemo
NCCN Guidelines V1 2018
4. Evolution of Radiotherapy
Fletcher and colleagues - (IJROBP 1984)
MSKCC data - Vikram et al
(head and neck surgery 1984)
Robertson et al-(clinic.oncology1998)
6. Questions to be answered
Pre op or Post op?
Dose?
Duration of treatment?
Indications for Adjuvant ChemoRT
Role of Targeted therapy
7. Pre op Vs Post op RT
RTOG 73-03
277 PATIENTS - FOLLOW UP 10 yrs
PRE OP RT POST OP RT
[ 50.0 GY ] [ 60.0 GY ]
• Loco regional control better (p = 0.04)
• No difference in absolute survival (p = 0.15)
• Complications same (p - NS)
IJROBP 1991;20:21-28
8. • Phase 3 RTOG 73-03 trial
• 354 LAHNSCC randomized to pre- and post op RT.
• LRC (48% vs 63%, p=0.03) and survival (26% vs 38%,
p=0.04)
• In favour of PORT for LAHNSCC.
9. Why need adjuvant therapy
after major surgery?
• Stage III/IV a/b cancers have a 30-40% 5 year
survival
• A more than 15% risk of recurrence has
traditionally been used to recommend
adjuvant therapy
Management of Head and Neck Cancer A Multidisciplinary Approach.
2nd ed. Philadelphia: J. B. Lippincott; 1994
11. Selecting patients?
Risk factors for recurrence
Primary
• positive or close (<5mm)
resection margin
• pT3/T4 tumours
• oral cavity site
• perineural invasion
• lymphovascular space
invasion
• Depth of invasion
• subglottic extension
Nodal
• Extra capsular extension
• 2 or more nodes or 2 or
more nodal stations
involved
• Node more than 3cm in size
Olsen KD et al Arch Otolaryngol Head Neck Surg 1994;120:1370-1374
Huang et al Int J Radiat Oncol Biol Phys 1992;23:737-742
12. Risk stratification of patients
Ang KK et al Int J Radiat Oncol Biol Phys 2001;51(3):571-8
Peters LJ et al. Int J Radiat Oncol Biol Phys 1993;26(1):3-11
18. Selecting patients
for intervention
MD Anderson Studies
• oral cavity, oropharynx,
hypopharynx. p T3 to T4 in
61%
• 58% had N2 to N3 neck
disease.
• 86% III/IV disease
Peters LJ et al. Int J Radiat Oncol Biol Phys 1993;26(1):3-11
Ang KK et al Int J Radiat Oncol Biol Phys 2001;51(3):571-8
• local–regional control
rate of 83%. = LOW
RISK, not for RT
19.
20. Does RT help in the
adjuvant setting?
Huang et al
Int J Radiat Oncol Biol Phys 1992
1982-88, 441 cases
125 ECS or positive margins 71 Surgery, 54
PORT.
LC@ 3 years S vs PORT:
• ECS: 31% vs 6% (P =0.03)
• positive margins, 41% vs 49% (P =0.04),
respectively; and
• ECS and positive margins: 0% and 68%
(P =0.001), respectively.
• multivariate analysis of local control
• use of PORT (P =0.0001)
• macroscopic
• extracapsular extension (P =0.0001)
• margin status (P =0.09) significantly
impacted local control. DFS@ 3 years
was 25vs 45%
Lundahl et al / Kao et al
Int J Radiat Oncol Biol Phys 1998/2008
95 patients with
node-positive squamous cell
carcinoma who were treated with
S +/- PORT
• 56 matched pairs of patients
were identified
• recurrence in the dissected
neck (RR=5.82; P =0.0002)
• death from any cause higher
for Surgery only group
(RR=1.67; P =0.0182)
Mishra RC et al Eur J Surg Oncol. 1996 Oct;22(5):502-4: PORT improves outcomes
21. Which patients may
NOT benefit from RT?
RT proven to reduce risk:
• Extra capsular extension
• Node positivity
• positive or close (<5mm)
resection margin
• Advanced T stage
What about other risk factors?
• pT1-T2 N0 tumours?
• perineural invasion
• lymphovascular space
invasion
• Depth of invasion
• subglottic extension
• Oral Cavity site
25. Management of Neck - Single node, NO ECS
Rec.
Surgery 11% 5/47
Surgery + port 0% 0/21
[Retrospective]
Barkley Am j Surg 1972
26.
27. Dose of Adjuvant treatment
Int J. Radiation Oncology Biology Physics Volume 26. Number I. 1993
28. RT details: Dose
Median dose of at least 60Gy
Even lower risk patients for RT have higher
relapse if <57.6Gy
For ECS and positive margins higher dose may
benefit
RT cannot compensate for suboptimal
margins/surgery
Pfreundner L. Int J Radiat Oncol Biol Phys 2000;47:1287-1297
29. RT : Overall time from Surgery
Egyptian studies: Hypothesis
generating (Better LC in higher
risk adjuvant patients)
MD Anderson:
Higher risk arm – Conv RT versus
Altered Frac
• Trend to better LC and DFS for
Altered Frac
• Delay of starting RT >6weeks
=poorer outcome
Overall time from Surgery to Rt
completion>100days= poorer
outcome
Ang KK et al Int J Radiat Oncol Biol Phys 2001;51(3):571-8
Rosenthal et al Head Neck 2002;24:115-126
30.
31. • Ang et al randomized post-operative high-risk HNSCC patients:
63 Gy delivered over 5 / 7 weeks. In the 7-week schedule,
prolonged interval between surgery and post-operative RT
associated with significantly lower local control and survival.
• 5yr LC: for an overall time of <11 weeks, LC 76%, compared to
62% for 11–13 weeks and 38% for >13 weeks (P = 0.002).
Hence post-operative RT should preferably
start within 6 weeks after surgery
Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features
and time factors of surgery plus radiotherapy in advanced head-and neck
cancer. Int J Radiat Oncol Biol Phys 2001;51:571–8.
42. Summary recommendations
Type of
intervention
Level 1
evidence
(strong)
Level 2 evidence Level 3
evidence
(weak)
CTRT (cisplatin
+RT)
Positive margins,
ECS, fit for CTRT
(age <70)
Close
margins
RT T3.T4 disease; Node
positive without ECS
irrespective of nodal
stations
Positive margins, ECS,
and NOT fit for CTRT
LVI, Depth of
invasion
47. MD Anderson Data
• Site matched control
• Stage was lower in NACT group (Mainly Taxane based)
• Hypothesis generation: Intense Taxane based NACT can
improve outcomes for matched groups?
48. • Post hoc analysis N2 disease ?? Better with TPF?
58. RT details: Target
• Use generous margins to prevent marginal failure
• Address contralateral neck when lymphatics could
communicate with contralateral side
59. Altered fractionation
Adjuvant studies:
• Trend to LC benefit
Increased acute toxicity
Opinion:
• To compensate for overall
treatment time, if needed
• Benefit may be in higher
risk patients, compared to
RT only
• Extra acute toxicity
• Logistically difficult
Sanguineti et al Int J Radiat Oncol Biol Phys 2005;61(3):762–71
Suwinski R et al Radiother Oncol 2008;87 (2):155–63
60. • Awwad et al, 46.2 Gy @ 1.2 Gy tid x 14 days vs td 60 Gy / 30#
• The 3-year locoregional control rate was significantly better in
the accelerated hyperfractionation (88+4%) than in the CF
(57+9%) group, P=0.01 (and this was confirmed by
multivariate analysis), but the difference in survival (60+10%
vs 46+9%) was not significant (P=0.29).
61.
62. OCAT TRIAL - TMH
• Assess post-operative adjuvant CCRT or accelerated
radiotherapy (6 instead of 5 fractions / week), on LRC
and OS in LAHNSCC oral cavity.
• Arm A: PORT; Arm B: PO-CCRT; Arm C: PO-AccRT.
• 5 year LRC for arms A and B was 59.9% and 65.1%
(arm B vs arm A: p = 0.203, HR: 0.83, 95% CI: 0.63 –
1.10) and 58.2% for arm C (arm C vs arm A: p = 1.02,
HR: 1.02, 95%CI: 0.78 – 1.30).
• Advanced T & N stage, tongue involvement, and ECE
had poorer outcomes but no significant difference in
LRC or OS between the three arms even with these
high risk features.
64. Phase III – SCCHN – (IHN01 study)
“Phase III, double-blind, placebo-controlled study of post-operative
adjuvant concurrent chemo-radiotherapy with or without nimotuzumab for
stage III/IV head and neck squamous cell cancer.”
s# Country
1 Singapore
2 Korea
3 India
4 Saudi Arabia
5 Cuba
6 Thailand
7 Australia
8 Indonesia
9 Malaysia
10 Philippines
65. Phase III , multicentric , randomized, two arms, controlled study.
–Stratified according to tumor primary site, nodal status, presence/absence of
microscopic margins/adverse features and investigator center
– Patients pool: Post-curative surgery: stages III, IV SCCHN
Clinical trial design
Resected,
SCCHN
stages
III/IV
710
patients
RT:60-66 Gy/ 30-
33f over 6-6.5
weeks, 5 f / week;
Cisplatin at 100
mg/m2 given on
days 1, 22 and 43
of RT, or 7 weekly
30 mg/msq
RT:60-66 Gy/ 30-33f over 6-6.5 weeks,
5 f / week;
Cisplatin at 100 mg/m2 given on days
1, 22 and 43 of RT, or 7 weekly 30
mg/msq
Nimotuzumab 200 mg weekly for 8
weeks concurrent with standard
radiation
R
a
n
d
o
m
i
z
at
io
n
ENDPOINT
1) DFS AT 2
YEARS
2) OS, tox at
5 years
219 patients
recruited till date
66. Adjuvant Targeted therapy
RTOG O234- Phase II- No benefit
RTOG0920- Phase III -Completed
EGF102988- Phase III – lapatinib- No benefit
IHNO1- completed - Phase III - Nimozitumab
67. Adjuvant treatment- Advanced Disease:
Take Home Message
Pre op vs post op- Post op better
Minimum Dose- 57.6 Gy in intermediate risk, > 60 Gy
in high risk.
Altered fractionation not proven benefit
Over all treatment time- within 100 days
Post op chemo RT- ECS or margin +Ve
Neoadjuvant chemo: benefit not proven, developing
Any targeted agent- No benefit